Physicians' Knowledge, Attitudes, and Perceptions about Medical Cannabis in the United States: A Scoping Review.

Q1 Medicine
Medical Cannabis and Cannabinoids Pub Date : 2025-05-14 eCollection Date: 2025-01-01 DOI:10.1159/000546264
Eleanor Yusupov, Stephanie Lopez, Maria A Pino
{"title":"Physicians' Knowledge, Attitudes, and Perceptions about Medical Cannabis in the United States: A Scoping Review.","authors":"Eleanor Yusupov, Stephanie Lopez, Maria A Pino","doi":"10.1159/000546264","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>As legalization of medical cannabis (MC) in the USA expands, there remains uncertainty in clinical guidance. Healthcare professionals remain unprepared to communicate to patients the therapeutic outcomes and possible adverse effects of MC utilization. There is limited training provided at all levels of medical education, even for professionals with many years of clinical practice. Additionally, there is minimal scientific research, which delays the development of evidence-based guidelines.</p><p><strong>Methods: </strong>This review followed established methodological approaches for scoping reviews according to PRISMA-ScR guidelines. Studies were included if they addressed the attitudes and beliefs of medical practitioners in the USA and were published after the year 2000.</p><p><strong>Results: </strong>There were forty-one studies from January 2013 to February 2025 included in the format of both electronic surveys and qualitative interviews. Participants included US physicians, other healthcare professionals, and medical trainees, representing multiple clinical specialties. Physicians reported lack of confidence in counseling patients or managing their use of MC. Oncologists, emergency medicine physicians, pain management specialists, and primary care physicians perceived that MC is beneficial for managing chronic pain, nausea, loss of appetite, depression, and other symptoms. Obstetric providers had unfavorable perceptions about perinatal use of MC. Physicians practicing in states where the drug has been legalized and those with greater years of practice were more comfortable recommending MC and counseling patients.</p><p><strong>Conclusions: </strong>US physicians and medical trainees perceived significant knowledge barriers to recommending MC and counseling patients on its therapeutic use. Implementing clear clinical practice guidelines, further education on these drugs in clinical curriculums, and enhancing continuing education offerings would improve prescriber confidence. Increased research could also assist medical professionals in appropriate clinical decision making.</p>","PeriodicalId":18415,"journal":{"name":"Medical Cannabis and Cannabinoids","volume":"8 1","pages":"58-64"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12162117/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Cannabis and Cannabinoids","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546264","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: As legalization of medical cannabis (MC) in the USA expands, there remains uncertainty in clinical guidance. Healthcare professionals remain unprepared to communicate to patients the therapeutic outcomes and possible adverse effects of MC utilization. There is limited training provided at all levels of medical education, even for professionals with many years of clinical practice. Additionally, there is minimal scientific research, which delays the development of evidence-based guidelines.

Methods: This review followed established methodological approaches for scoping reviews according to PRISMA-ScR guidelines. Studies were included if they addressed the attitudes and beliefs of medical practitioners in the USA and were published after the year 2000.

Results: There were forty-one studies from January 2013 to February 2025 included in the format of both electronic surveys and qualitative interviews. Participants included US physicians, other healthcare professionals, and medical trainees, representing multiple clinical specialties. Physicians reported lack of confidence in counseling patients or managing their use of MC. Oncologists, emergency medicine physicians, pain management specialists, and primary care physicians perceived that MC is beneficial for managing chronic pain, nausea, loss of appetite, depression, and other symptoms. Obstetric providers had unfavorable perceptions about perinatal use of MC. Physicians practicing in states where the drug has been legalized and those with greater years of practice were more comfortable recommending MC and counseling patients.

Conclusions: US physicians and medical trainees perceived significant knowledge barriers to recommending MC and counseling patients on its therapeutic use. Implementing clear clinical practice guidelines, further education on these drugs in clinical curriculums, and enhancing continuing education offerings would improve prescriber confidence. Increased research could also assist medical professionals in appropriate clinical decision making.

医生的知识,态度和看法在美国医用大麻:范围审查。
导读:随着医用大麻(MC)在美国合法化的扩大,临床指导仍存在不确定性。医疗保健专业人员仍然没有准备好与患者沟通使用MC的治疗结果和可能的不良影响。各级医学教育提供的培训有限,即使对具有多年临床实践经验的专业人员也是如此。此外,科学研究很少,这延误了以证据为基础的指导方针的制定。方法:本综述按照PRISMA-ScR指南建立的范围评价方法学方法。如果研究涉及美国医疗从业人员的态度和信念,并在2000年以后发表,则纳入研究。结果:2013年1月至2025年2月共纳入41项研究,采用电子调查和定性访谈的形式。参与者包括美国医生、其他医疗保健专业人员和医学实习生,代表多个临床专业。据报告,医生在咨询患者或管理其使用MC方面缺乏信心。肿瘤学家、急诊医学医生、疼痛管理专家和初级保健医生认为,MC有利于控制慢性疼痛、恶心、食欲不振、抑郁和其他症状。产科医生对围产期使用MC持不利看法。在药物已合法化的州执业的医生和那些执业多年的医生更愿意推荐MC并为患者提供咨询。结论:美国医生和医学实习生在推荐MC和咨询患者使用MC治疗方面存在显著的知识障碍。实施明确的临床实践指南,在临床课程中对这些药物进行进一步教育,并加强继续教育,将提高开处方者的信心。增加研究也可以帮助医疗专业人员作出适当的临床决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Medical Cannabis and Cannabinoids
Medical Cannabis and Cannabinoids Medicine-Complementary and Alternative Medicine
CiteScore
6.00
自引率
0.00%
发文量
18
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信